Trial Profile
A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2019
Price :
$35
*
At a glance
- Drugs RX 10045 (Primary)
- Indications Postoperative inflammation; Postoperative pain
- Focus Therapeutic Use
- 28 Dec 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 05 Jan 2015 New trial record